Agoracom: Small Cap Investment - Zenith Epigenetics - Enzalutamide effective in non-metastatic prostate cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Enzalutamide effective in non-metastatic prostate cancer

posted on Jun 28, 2018 04:26PM

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

https://www.ncbi.nlm.nih.gov/pubmed/29949494

"Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo."

This would actually be really good for Zenith's combo therapy. More patients on enzalutamide equals more patients developing enzalutamide resitance = more opportunity for ZEN-3694/enzalutamide combo

7 Recommendations

Re: Enzalutamide effective in non-metastatic prostate cancer

BearDownAZ

Jun 29, 2018 10:51AM

Reply New Message

Back To Forum List View

Please to post a reply